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Objective. To examine the heterogeneity of global
transcriptome patterns in systemic sclerosis (SSc) skin in
a large sample of patients with SSc and control subjects.
Methods. Skin biopsy specimens obtained from 61
patients enrolled in the Genetics versus Environment in
Scleroderma Outcome Study (GENISOS) cohort and 36
unaffected control subjects with a similar demographic
background were examined by Illumina HumanHT-12
bead arrays. Followup experiments using quantitative
polymerase chain reaction and immunohistochemical
analysis were also performed.
Results. We identified 2,754 differentially expressed
transcripts in SSc patients compared with controls. Clus-
tering analysis revealed 2 prominent transcriptomes in
SSc patients: the keratin and fibroinflammatory signa-
tures. Higher keratin transcript scores were associated
with shorter disease duration and interstitial lung disease,
while higher fibroinflammatory scores were associated
with diffuse cutaneous involvement, a higher skin score at
the biopsy site, and a higher modified Rodnan skin thick-
ness score. A subgroup of patients with significantly longer
disease duration had a normal-like transcript pattern.
Analysis of cell type–specific signature scores revealed
remarkable heterogeneity across patients. Significantly
higher scores were calculated for fibroblasts (72% of
patients), microvascular cells (61%), macrophages (54%),
and dendritic cells (DCs) (49%). The majority of samples
with significantly higher fibroblast scores (35 of 44 [80%])
had significantly increased macrophage and/or DC scores.
Further analysis and immunohistochemical staining indi-
cated that the keratin signature was not a general marker
of keratinocyte activation but was in fact associated with
an activation pattern in hair and adnexal structures.
Conclusion. Prominent fibroinflammatory and ker-
atin signatures are present in SSc skin. Expression profiles
of SSc skin show significant heterogeneity, and this finding
might be useful for stratifying patients for targeted thera-
pies or predicting the response to immunosuppression.
Systemic sclerosis (SSc; scleroderma) is a multi-
system autoimmune disease associated with high mor-
bidity and mortality (1). Global gene expression
profiling with microarrays allows an unbiased genome-
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wide assessment of the transcript dysregulation in a
given tissue. This technology is now increasingly used to
fingerprint pathologic processes, stratify diseases at the
molecular level, and predict disease outcome (2–6).
Development of effective treatment options in SSc has
been hampered by a lack of sufficient understanding of
its pathophysiology. Global gene expression studies in
SSc at the end-organ level (7–10) or in peripheral blood
cells (11–15) have indicated the presence of distinct
transcript patterns in the majority of patients.
Skin is a prominently affected and easily accessi-
ble end-organ in SSc. Previous global gene expression
studies have shown that SSc skin has a distinct gene
expression profile, with inflammatory as well as fibrotic
signatures (7,10). In a larger study involving 24 patients
with SSc, the subgroup of patients with diffuse cutane-
ous SSc (dcSSc) could be divided into 3 distinct groups
and the patients with limited cutaneous SSc (lcSSc) into
2 groups based on the intrinsic gene expression profiles
observed in their skin biopsy specimens. A subgroup of
patients including those with dcSSc and those with lcSSc
showed an inflammatory pattern. Another subgroup of
SSc patients with diffuse skin involvement showed a
proliferative gene expression profile. A third subgroup
of patients had a “normal-like” gene expression signa-
ture (9). Two other studies by the same group of investi-
gators confirmed the presence of these 3 intrinsic
subsets in independent samples (inflammatory, prolifer-
ative, and normal-like) (16,17).
In the present study, we investigated the he-
terogeneity of SSc transcript profiles in a large, well-
characterized sample using a comprehensive gene
expression profiling platform. First, we examined the
impact of skin status (affected versus unaffected) on the
SSc gene expression profile. Second, we identified 2
gene expression signatures in our large data set and
examined the relationship between these signatures and
SSc clinical features and previously described intrinsic
transcript signatures (9). Last, we investigated the spe-
cific contribution of different cell types present in the
skin (e.g., fibroblasts or macrophages) to the observed
transcript heterogeneity in SSc skin.
PATIENTS AND METHODS
Patients and control subjects. Sixty-one patients were
recruited from the Genetics versus Environment in Scleroder-
ma Outcome Study (GENISOS) (18) or at the baseline visit in
an investigator-initiated, open-label phase I/IIa study of imati-
nib (19). In addition to samples obtained at baseline, followup
samples were also obtained from 5 of the 61 patients enrolled
in the GENISOS cohort. All patients fulfilled the American
College of Rheumatology/European League Against Rheuma-
tism classification criteria for SSc (20). We also investigated 36
control subjects who had a similar demographic background.
The study protocol was approved by the institutional review
boards of the participating institutions, and all participants
provided fully informed, voluntary consent.
Disease type was defined based on the extent of skin
involvement (21). Patients who had diffuse skin involvement at
any time during their disease course were categorized as having
dcSSc. The modified Rodnan skin thickness score (MRSS) (22)
was used to assess skin involvement, and the skin score at the
biopsy site was also recorded (0–3 scale, where 05 not involved
and 35 severe thickening). The presence of moderate to severe
interstitial lung disease (ILD) was defined as a forced vital
capacity of ,70% predicted and findings indicative of pulmo-
nary fibrosis on high-resolution computed tomography of the
chest. Patients were considered as being treated with immuno-
suppressive agents if they had received immunosuppressive
medication within 4 weeks of skin biopsy (with the exception of
prednisone at a dose of#5 mg or hydroxychloroquine).
Skin biopsy and quantitative reverse transcription–
polymerase chain reaction (qRT-PCR) analysis. Three-millime-
ter punch biopsy samples of skin were obtained from the arms
of the study subjects and were immediately immersed in RNA-
later solution (Qiagen) and stored at 2808C. RNA was
extracted using RNeasy Fibrous Tissue kits (Qiagen). Global
gene expression was assessed using Illumina HumanHT-12
bead arrays. All microarray experiments were performed in a
single batch (see Supplementary Methods, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39289/abstract). Microarray data from this
study are available from NCBI GEO (http://www.ncbi.nlm.nih.
gov/geo/) using accession no. GSE58095. There is overlap with
accession no. GSE47162, but the previous data set does not
include any control samples.
Quantitative RT-PCR was also performed for 2 promi-
nently overexpressed keratin transcripts, keratin 25 (type I
keratin) and keratin 85 (type II keratin) to confirm the micro-
array results. In these experiments, the expression values were
normalized to those of GAPDH. Relative quantification was
performed using the Ct method, where DDCt values were cal-
culated based on GAPDH and transcript levels in controls.
Immunohistochemical analysis. Immunohistochemical
analysis for 2 general markers of epidermis activation (keratin
6 and keratin 16) and keratin 85 (which was prominently over-
expressed in our samples) was performed in skin biopsy sam-
ples obtained from 5 SSc patients with the keratin transcript
signature and from unaffected control subjects (matched for
age, sex, and ethnicity), as well as in a biopsy sample from pso-
riatic skin (positive control) (see Supplementary Methods,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract).
Microarray data analysis. Raw data were analyzed
with BRB ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.
html). Data were normalized according to the quantile method.
Genes whose log intensity variance was in the bottom 75th per-
centile were filtered out, and 11,819 transcripts met this criteri-
on. Differentially expressed genes were detected using
Significance Analysis of Microarrays (SAM), at a false discovery
rate of ,5% (23). The sets of differentially expressed genes
were also modeled using Ingenuity Pathways Analysis (IPA)
software, and upstream regulators were identified. The goal of
Upstream Regulator Analysis in IPA is to identify upstream
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regulators and predict whether they are activated or inhibited,
given the observed gene expression changes in the experimental
data set. IPA uses a Z score algorithm to make predictions. The
Z score algorithm is designed to reduce the chance that random
data will generate significant predictions. Upstream Regulator
Analysis is based on expected causal effects between upstream
regulators and targets; the expected causal effects are derived
from the literature compiled in Ingenuity Knowledge Base.
Composite transcript scores for the keratin and
fibroinflammatory signatures were also calculated. For this
purpose, we normalized each transcript included in the pro-
files to mean5 0 and variance5 1. To derive the composite
score, we averaged the expression values of the positively cor-
related genes with the inverse values of the negatively correlat-
ed genes. We also calculated a composite score for predicted
activation of the Wnt/b-catenin pathway based on a previously
published data set, using the above algorithm (24). The statis-
tical methods used to examine the relationship between these
transcript composite scores and clinical outcomes depended
on the distribution of composite scores (dependent variable).
The distribution of the keratin scores was right skewed. There-
fore, nonparametric methods were used for analysis of the ker-
atin scores. Specifically, Spearman’s rho was used if the
independent variable was continuous, and Wilcoxon’s rank
sum test was used if the independent variable was categorical.
Parametric tests were used for analysis of the composite
fibroinflammatory scores (Pearson’s correlation and linear
regression).
Analysis of cell type–specific expression. Skin con-
sists of a complex set of cell types, each of which contributes to
the aggregate expression data generated from a given biopsy.
We performed cell type–specific expression analysis according
to the approach previously described by our group (25), to
investigate the potential contribution of these cell types to the
SSc skin transcript profile (see Supplementary Methods, available
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39289/abstract).
RESULTS
Sixty-one patients with SSc and 36 control sub-
jects were assessed in this study. The demographic and
clinical characteristics of the study population are shown
in Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39289/abstract.
Skin thickening at the biopsy site is a promi-
nent source of heterogeneity. The transcriptome of the
majority of SSc patients differed from that of control
subjects. There were 2,754 differentially expressed genes
in SSc patients compared with controls (see Additional
Tables 1 and 2, available on the Arthritis & Rheumatolo-
gy web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39289/abstract). IPA revealed that the top 3 repre-
sented canonical pathways belonged to hepatic fibrosis,
agranulocyte adhesion/diapedesis, and granulocyte adhe-
sion/diapedesis. The top significantly activated upstream
transcription regulators were interferon (IFN) regulatory
factor 7 (IRF-7), NF-kb, IRF-1, STAT-1, and tumor pro-
tein 53, while the top upstream activated cytokines/growth
factors were transforming growth factor b1 (TGFb1),
IFNa, oncostatin M, IFNa2, and IFNg (see also Supple-
mentary Figure 1 and Additional Table, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39289/abstract). Next, we exam-
ined the SSc gene profile based on the status of skin
involvement at the biopsy site (Figure 1); a complete list
of differentially expressed transcripts in all comparison
groups is shown in Additional Table 1 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39289/abstract).
A comparison of patients with clinically affected
skin at the biopsy site and control subjects revealed
4,184 differentially expressed transcripts belonging to
hepatic fibrosis, agranulocyte adhesion/diapedesis, and
dendritic cell (DC) maturation, while a comparison of
SSc patients with clinically unaffected skin at the biopsy
site and controls resulted in only 24 differentially
expressed genes (the small number of differentially
expressed transcripts in this comparison precluded a
meaningful pathway analysis). Furthermore, we detected
prominent gene expression differences between SSc
Table 1. Clinical correlates of keratin, fibroinflammatory, and normal-like signatures*
Clinical variable
Keratin score Fibroinflammatory score Clustering with controls
rs P† r b (95% CI) P b or OR (95% CI) P
Male sex NA 0.658 NA 0.15 (20.15, 0.46) 0.319 1.22 (0.34, 4.37) 0.820
Diffuse cutaneous involvement NA 0.179 NA 0.39 (0.12, 0.67) 0.006 0.46 (0.14, 1.54)‡ 0.212
Immunosuppressive agents NA 0.902 NA 0.11 (20.41, 0.2) 0.488 0.68 (0.18, 2.62)‡ 0.513
Interstitial lung disease NA 0.017 NA 0.14 (20.14, 0.41) 0.33 0.43 (0.11, 1.65)‡ 0.183
Affected skin at biopsy site NA 0.658 NA 0.54 (0.29, 0.78) ,0.001 0.46 (0.14, 1.51)‡ 0.197
Disease duration 20.32 0.02 20.19 20.02 (20.05, 0.01) 0.165 3.22 (0.11, 6.34)‡ 0.043
Concurrent MRSS 0.03 0.85 0.66 0.03 (0.02, 0.04) ,0.001 25.02 (211.28, 1.24) 0.114
Skin score at biopsy site 0.01 0.98 0.55 0.31 (0.18, 0.43) ,0.001 20.47 (21.02, 0.09) 0.1
* 95% CI5 95% confidence interval; NA5 not applicable; MRSS5modified Rodnan skin thickness score.
† Calculated using Wilcoxon’s rank sum test, because the keratin transcript scores were strongly right skewed.
‡ Odds ratio (OR).
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patients with clinically affected skin at the biopsy site and
those with unaffected skin at the biopsy site. This com-
parison resulted in 142 differentially expressed transcripts
belonging to the top 3 overrepresented canonical
pathways.
We also performed a parallel analysis in order to
investigate whether the heterogeneity based on the sta-
tus of skin at the biopsy site is driven by disease type. In
a comparison between patients with dcSSc and controls,
there were 3,983 differentially expressed transcripts
belonging to hepatic fibrosis, DC maturation, and graft-
versus-host signaling, while 71 differentially expressed
transcripts were detected in a comparison between
patients with lcSSc and controls, with overrepresenta-
tion of the hepatic fibrosis pathway. Of note, there were
no differentially expressed transcripts when patients
with dcSSc were compared with those with lcSSc, indi-
cating that the status of skin at the biopsy site is a more
prominent source of heterogeneity than is disease type.
Of note, a pairwise comparison between affected and
unaffected skin within the same individual SSc patients,
as previously performed (9,10,16,17), could not be con-
ducted in our study, because biopsy samples obtained
from other typically uninvolved anatomic areas such as
the buttock area were not performed.
Differentially expressed gene expression pro-
files in SSc patients. Figure 2 shows the unsupervised
hierarchical clustering of 2,754 differentially expressed
genes identified in the comparison between SSc samples
and controls (for additional information see Supple-
mentary Figure 2, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39289/abstract). Two partially overlapping gene
clusters were overexpressed in SSc patients (Figure 2).
The first gene cluster was highly enriched with keratins
and keratin-associated proteins (mainly hair and adnex-
al structure keratins), with 77 of 93 transcripts (82.8%)
being keratin-related (see Additional Table, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract).
Thirty-four patients (57.6%), including those with clinically
affected skin and those with unaffected skin (see
Supplementary Figure 3, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39289/abstract), as well as both patients with lcSSc
and patients with dcSSc, clustered in the group with overex-
pression of the keratin signature (data not shown). The ker-
atin signature was significantly less common among control
subjects (present in only 8 controls [22.2%]; P5 0.002).
We also investigated levels of 2 representative keratin
transcripts, keratin 25 and keratin 85, by qRT-PCR. As
shown in Supplementary Figure 4 (available on the
Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39289/abstract), levels of both
keratin 25 (type I keratin) and keratin 85 (type II kera-
tin) were significantly higher in patients compared with
controls (median fold changes 21.1 [P5 0.015] and 15.7
[P5 0.003], respectively).
The second overexpressed cluster was enriched
with genes involving inflammatory (including IFN-
inducible genes) and fibrotic pathways, such as THY1,
COL1A1, COMP, OAS1, and CCL2 (Figure 2; see also
Additional Table, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39289/abstract). As shown in Supplementary
Figure 5 (available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39289/abstract), this fibroinflammatory signature was
present in 44 patients (74.6%), while only 5 control sub-
jects had this signature (P , 0.001). IPA of this cluster
Figure 1. Numbers of differentially expressed (DE) genes in systemic sclerosis (SSc) patients with affected skin at the biopsy site compared with
those with unaffected skin at the biopsy site and control subjects (A) and in patients with diffuse SSc compared with those with limited SSc and
control subjects (B).
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revealed that the top 3 overrepresented canonical
pathways were hepatic fibrosis, agranulocyte adhesion/
diapedesis, and DC maturation. In this cluster, genes
belonging to inflammatory and fibrotic pathways were
coexpressed. As shown in Figure 2, this gene cluster par-
tially overlapped with the keratin signature. Similar to
previously published data (9), 14 SSc samples (23.7%)
clustered with control samples (Figure 2; see also Sup-
plementary Figure 2, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39289/abstract).
Cross comparison with the inflammatory and
proliferative intrinsic subsets. We mapped the inflam-
matory intrinsic subset (60 genes corresponding to 93
probes) and the proliferative intrinsic subset (56 genes cor-
responding to 86 probes) previously described by Milano
et al (9) to probes present on Illumina HumanHT-12
arrays. As shown in Supplementary Figure 6 (available on
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39289/abstract), some patient
samples showed increased coexpression of transcripts in the
inflammatory intrinsic subset, but we did not observe homo-
geneous overexpression of proliferative intrinsic genes
among patient samples (see Supplementary Figure 7,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract). We
also investigated the overlap between the above-mentioned
fibroinflammatory cluster and these 2 intrinsic gene subsets.
Twenty inflammatory intrinsic genes (23 probes) were also
present in our fibroinflammatory cluster, whereas only 5
genes were in common between the proliferative intrinsic
gene subset and our fibroinflammatory gene cluster.
We also performed a hierarchical clustering ana-
lysis using unbiased selection of genes that deviated at
least 2-fold from the mean in at least 5 samples in order
to parallel the analytic approach described in previous
SSc skin gene expression studies (9,10). Following this
approach, 1,870 genes were identified. As shown in Sup-
plementary Figure 8 (available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.39289/abstract), unsupervised hierarchical
clustering using this gene list demonstrated that a sub-
group of SSc samples (especially those from patients
with affected skin) clustered together. Furthermore,
there were clusters of genes that corresponded to the
samples with an intrinsic inflammatory signature (9)
and the above-described keratin signature, but samples
with a prominent intrinsic proliferative signature (9)
and their corresponding genes could not be detected.
Furthermore, 13 of 58 genes in the inflammatory intrin-
sic signature overlapped with our list of 1,870 transcripts
(P , 0.001, odds ratio [OR] 3.48, 95% confidence inter-
val [95% CI] 1.89–6.41), while only 1 of 55 genes in the
proliferative intrinsic signature overlapped with this
Figure 2. Unsupervised hierarchical clustering of skin samples based on the 2,754 transcripts that were differentially expressed in clinically
affected systemic sclerosis (SSc) skin, unaffected SSc skin, and control skin. The orange bars and purple bars on the left indicate keratin and
fibroinflammatory gene clusters, respectively.
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gene list (P5 0.127, OR 0.32, 95% CI 0.06–1.61). This
indicates that the previously described inflammatory
intrinsic signature (9) had significant overlap with our
list of 1,870 genes, while the proliferative intrinsic genes
did not show a significant overlap with the genes that
have highly varying levels in our data set.
Correlates of keratin and fibroinflammatory
signatures. Next, we calculated composite scores for
the keratin and fibroinflammatory clusters. As shown in
Supplementary Figure 9 (available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39289/abstract), both clusters showed
higher composite scores in patients compared with con-
trols (P , 0.001 for the keratin cluster and P , 0.001
for the fibroinflammatory clusters).
Table 1 shows clinical correlates of these 2 com-
posite transcript scores. A higher composite keratin score
was associated with shorter disease duration and the
presence of ILD, while a higher composite fibroinflam-
matory score was associated with a higher MRSS, local
skin score, and diffuse cutaneous involvement. Compos-
ite scores were not associated with SSc-related antibodies
(data not shown) or treatment with immunosuppressive
agents.
Examination of clinical correlates in the 14 SSc
patients with a “normal-like signature” revealed that they
had a significantly longer disease duration. In addition, a
composite score for predicted activation of the Wnt/b-cat-
enin pathway in our data set based on a previously pub-
lished gene list (24) was calculated. Both the keratin and
fibroinflammatory composite scores were significantly cor-
related with the Wnt/b-catenin composite scores (rs5 0.29
[P5 0.004] and r5 0.56 [P, 0.001], respectively).
Analysis of cell type signature scores. As shown
in Figure 3, the 1,604 overexpressed transcripts in SSc
skin were enriched in genes specifically expressed in
fibroblasts, macrophages, microvascular tissue, and
DCs. Similarly, the 1,150 underexpressed transcripts
were enriched in genes specifically expressed in lympho-
cytes (NK cells, CD41 and CD81 T cells, and B cells),
and epidermis-related cell types (melanocytes, keratino-
cytes, and hair outer root sheath [ORS] cells). Again,
calculation of cell type signature scores revealed signifi-
cant heterogeneity across patients.
At the individual patient level (Figure 4), signifi-
cantly higher scores were more frequently calculated for
fibroblasts (72% of patients), indicating that genes specif-
ically expressed in fibroblasts were increased in most of
the biopsy specimens from patients with SSc (for addi-
tional information, see Supplementary Figure 10, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39289/abstract).
Similarly, in the majority of patients, we calculated sig-
nificantly higher signature scores for microvascular and
macrophage-related transcripts. Consistent with coex-
pression of fibrotic and inflammatory transcripts in our
Figure 3. Genes differentially expressed in systemic sclerosis (SSc) skin samples (versus control samples). Enrichment with genes specifically
expressed in certain cell types is shown. Genes were ranked according to the degree to which they were specifically expressed in each of 14 cell
types. Enrichment statistics quantify the degree to which genes that were significantly increased (A) or decreased (B) in SSc skin samples are
among the genes specifically expressed with respect to each cell type. Positive enrichment statistics denote enrichment of differentially expressed
genes with respect to genes most specifically expressed in a given cell type. Negative enrichment statistics denote enrichment of differentially
expressed genes with respect to genes showing specifically low expression in a given cell type. **5P , 0.001 by Wilcoxon’s rank sum test.
DC5 dendritic cell; KC5 keratinocyte; ORS5 outer root sheath; NK5 natural killer.
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unsupervised hierarchical clustering experiments, the
majority of samples with significantly higher fibroblast
scores (35 of 44 [80%]) had significant macrophage
and/or DC scores. Furthermore, the top cell–based pro-
files correlating with the fibroinflammatory signature in
the initial clustering (Figure 2) were macrophage genes
(r5 0.75, P , 0.005) and fibroblast genes (r5 0.68, P ,
0.001). There was also a subgroup of patients with ele-
vated expression of hair ORS–specific genes; the top
cell-based profiles correlating with the keratin signa-
ture in the initial clustering (Figure 2) were hair ORS
genes (rs5 0.44, P , 0.001) and keratinocyte genes
(rs5 0.38, P , 0.001).
Longitudinal progression of the keratin sig-
nature. In an exploratory investigation, we examined
the longitudinal progression of the above-mentioned
signatures (Figure 2) in 5 patients. The keratin signature
increased numerically over time in the 2 patients with
early disease (disease duration ,2 years), while it
declined numerically in the remainder of the patients (see
Supplementary Figure 11, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39289/abstract). The fibroinflammatory
score showed less variation over time, although a down-
ward trend over time was observed in the majority of
samples (see Supplementary Figure 11). None of the
observed changes reached statistical significance, which
might be attributable to the small sample size (n5 5).
Immunohistochemical studies of the keratin
signature. As shown in Figure 5, keratin 6 and keratin
16 staining in SSc skin samples (5 with a keratin signa-
ture) and matched controls was confined to hair follicles
Figure 4. Hierarchical clustering of patients with systemic sclerosis
based on cell type signature scores. Each row represents a patient
sample. Transcript scores for each patient were calculated with
respect to 14 cell types. Scores were calculated based on fold-change
estimates for 125 signature genes per cell type (expression in patient
samples/average expression in 36 control samples). Triangles denote
scores that are significantly high () or low () compared with all
other human genes. Values in the 2 bottom rows are the percentages
of patients with significantly high (red) or low (blue) scores.
KC5 keratinocyte; ORS5outer root sheath; NK5 natural killer;
DC5 dendritic cell.
Figure 5. Representative images showing keratin 6 (KRT6),
KRT16, and KRT85 staining of skin tissue from patients with sys-
temic sclerosis (SSc) with a keratin transcript signature (n5 5) and
unaffected control subjects (n5 5). Psoriatic skin was used as a posi-
tive control for KRT6 and KRT16. Arrows indicate hair follicles.
Original magnification 3 400.
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and eccrine sweat glands, whereas there was diffuse
staining of the epidermis in a sample of psoriatic skin
(positive controls). The keratin 85 staining was confined
to hair matrix/precortex and hair cuticle in all 3 sample
types (SSc, psoriasis, and controls) and was not present
in the epidermis.
DISCUSSION
In the present study, we investigated the global
gene expression profile in a large sample of patients
with SSc and control subjects, using a comprehensive
microarray platform to dissect the heterogeneity of tran-
scriptome patterns in affected SSc skin. SSc skin sam-
ples showed prominent fibroinflammatory and keratin
transcript profiles that correlated with certain disease
features. Furthermore, we performed a cell-based mod-
ular analysis that showed substantial heterogeneity in
the inflammatory profile of SSc skin. These findings
may have important implications for identification of
therapeutic targets and development of biomarkers.
A prominent fibroinflammatory signature corre-
lating with the MRSS and the local skin score was pre-
sent in the majority of SSc skin samples. Hierarchical
clustering and cell type–specific signature scores indicat-
ed that inflammatory and fibrotic signatures coexist in
most patients. As expected, the majority of patients in
the current study (72%) displayed significant up-
regulation of the fibroblast cell-type signature, while the
overall inflammatory profile of SSc patients showed sig-
nificant heterogeneity. This heterogeneity might provide
important information for stratifying patients for targeted
therapies and/or responses to general immunosuppres-
sion. The DC/macrophage modules were the most com-
monly up-regulated inflammatory modules (.50%),
whereas NK cell, CD4, and CD8 T cell modules were up-
regulated in only 10%, 18%, and 21% of cases, respec-
tively. A similar analysis in psoriatic plaques revealed a
more inflammatory and less fibrotic profile. In patients
with psoriasis, the majority of samples displayed height-
ened macrophage, DC, NK cell, and CD8 T cell signa-
tures, while only 9% of samples showed up-regulation of
the fibroblast signature (25). This finding is also clinically
plausible, because psoriatic plaques are more responsive
to immunosuppression than is SSc skin.
Full-thickness skin biopsy specimens consist of a
heterogeneous collection of cell types, each of which
contributes to the aggregate expression measurement
for any individual gene. However, few previous global
gene expression studies in SSc skin have included analy-
ses to relate the observed transcript heterogeneity to
cell-specific signatures. Whitfield et al (10) measured
gene expression in 11 different cell lines grown in cul-
ture that represent cell types likely to be present in skin.
A comparison of the transcript profile of these cell lines
with skin samples revealed that SSc skin had prominent
dysregulation of fibroblast- and endothelial-related
genes. Gardner et al (7) examined the gene expression
profile of SSc skin and concomitantly collected explanted
passage 4 fibroblasts. A comparison of skin and fibroblast
transcriptomes showed that a subgroup of differentially
expressed transcripts are likely to be of fibroblast origin,
while other cell types were also required for full expres-
sion of the SSc phenotype. Composite scores for the cell-
specific signatures were not calculated in either of those
studies.
Pendergrass et al (17) also performed a cell type–
specific analysis based on 2 previously published data
sets (26,27). Similar to our analysis, a composite score
was calculated for cell-based gene signatures. However,
we have here calculated a rank-based signature score
statistic while using a novel and large collection of data
samples to identify signature genes for each cell type
(25,28,29). Pendergrass et al also observed significant
heterogeneity in the SSc skin inflammatory profile.
However, a cross-comparison between their specific cell
type signatures and our results is difficult, because the
cell types were defined differently. Similar to our
results, a prominent fibroblast signature in patient sam-
ples was observed. The most prominent inflammatory
cell signature in the Pendergrass study was the granulo-
cyte signature, while the macrophage signature was the
most prominent inflammatory signature in our study.
Those investigators also reported a combined signature
for myeloid cells that was present in the majority of
patients.
We also investigated the presence of previously
described intrinsic inflammatory and fibrotic signatures
(9,16,17) in our data set. A subset of SSc samples showed
an increased coexpression pattern for the intrinsic
inflammatory transcripts, but this was not observed for
the intrinsic proliferative transcripts. In the present study,
we not only included a larger number of patients but also
investigated a substantially higher number of control sub-
jects with a similar demographic background (36 control
subjects in the present study versus 6–10 in previous stud-
ies [9,16,17]). This larger number increased the power to
detect differentially expressed transcripts and better
reflects the heterogeneity within each study population
(patients and controls) during the clustering analysis.
Furthermore, we used a platform that includes 54%
more genes (30,500 versus 19,800), allowing us to per-
form a more comprehensive investigation of SSc skin.
For example, only 55.1% of keratin signature genes were
TRANSCRIPTOME PROFILING OF SYSTEMIC SCLEROSIS SKIN 3023
present in the previously used platform (16,17). Based on
our results, it seems prudent to continue broader molecu-
lar profiling of SSc skin to characterize the transcript dys-
regulations most relevant for understanding disease
mechanisms, creating subsets, identifying therapeutic tar-
gets, and developing biomarkers.
We observed a prominent keratin signature in
SSc skin, which is a novel finding. Previous research
mainly focused on molecular dysregulations in the der-
mal layer of SSc skin, although phenotypic changes in
the skin such as hypopigmentation or hyperpigmenta-
tion also imply involvement of the epidermis (30). Previ-
ous studies have also indicated overexpression of the
key cytokines TGFb (31), monocyte chemotactic pro-
tein 1 (32), vascular endothelial growth factor (33), and
interleukin-2 receptor (34) in SSc epidermis. A proteo-
mic analysis of lesional scleroderma skin showed promi-
nent dysregulation of proteins specific to epidermal
differentiation in addition to those involved in extracel-
lular matrix production and myofibroblast contractility
(35). In a followup study, epidermal keratinocyte matu-
ration was delayed, and an activation pattern with up-
regulation of keratin 6 and keratin 16 was observed in
both clinically involved and uninvolved skin of patients
with early dcSSc. Furthermore, coculture of epidermis
from SSc patients and normal human fibroblasts pro-
moted fibroblast contractility to the extent observed
with TGFb, while epidermis from healthy controls did
not have a similar effect (36).
Similar to the above-mentioned study (36), the
keratin transcript signature was present in involved and
uninvolved skin in the present study. However, our
immunohistochemical staining results did not indicate
that the keratin signature that we observed was a mark-
er of general activation of keratinocytes, as seen in pso-
riatic skin (25). Specifically, keratin 6 and keratin 16,
both of which are usually expressed only in hair and
eccrine sweat glands but show broad epidermal staining
in diseases with general activation of keratinocytes (e.g.,
psoriasis), did not show a broad epidermal staining
pattern in SSc patients with the keratin signature. The
keratin signature consisted mainly of up-regulation of
hair- and adnexal structure–related keratins. Consistent
with this notion, keratin 85 staining was confined to hair
follicles and eccrine sweat glands. Of note, we do not
believe that the observed keratin signature is due to the
higher number of hair follicles in SSc patients, because
the same anatomic site was biopsied in patients and con-
trols. Furthermore, there was no association between
the keratin signature and male sex.
The observed association between the keratin
signature and shorter disease duration supports the
notion that this transcript profile is a time-dependent
occurrence. The observed keratin signature might be a
response of the hair follicle to the molecular changes in
SSc skin. Hair follicle morphogenesis and growth are
regulated through complex and reciprocal epithelial
mesenchymal interactions. The dermal papilla is essen-
tial for follicle formation in the embryo and for initiating
the next period of hair growth in adults (37). Activation
of Wnt/b-catenin signaling is an important stimulator of
new hair growth and differentiation (38–40). In our data
set, the keratin signature correlated with the predicted
activation of the Wnt/b-catenin pathway, supporting the
notion that the up-regulation of this pathway in SSc (41)
might contribute to the observed keratin signature. The
observed association of the keratin signature with ILD
might also stem from common upstream regulators for
ILD and this transcript signature. Further studies are
needed to investigate the potential role of this signature
in the pathogenesis of SSc. In general, our results pro-
vide further evidence for the presence of molecular dys-
regulation in several skin compartments (not only
dermis) in SSc.
Similar to what was observed in previous studies,
a subset of patients showed normal-like gene expression
profiles (7,9,16,17). These patients had a significantly
longer disease duration, and a trend for association of a
normal-like signature with longer disease duration was
observed in a previous SSc skin data set (17). This find-
ing is also supported by the decreasing composite
fibroinflammatory scores observed in our pilot longitu-
dinal study (see Supplementary Figure 11, available on
the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.39289/abstract). Patients
with a normal-like transcript profile also tended to have
milder disease (lower MRSS and lower skin score at the
biopsy site), although these findings did not reach statisti-
cal significance.
Patients in whom skin at the biopsy site was
affected were more likely to have a distinct gene expres-
sion profile and a higher composite fibroinflammatory
score. However, we were unable to compare the gene
expression profile of skin biopsy specimens obtained
from 1 affected area (e.g., the arm) and 1 unaffected
area (usually the buttock or back) in the same individu-
al, because biopsies of the buttocks area were not per-
formed in our study. Furthermore, the number of
differentially expressed genes in clinically affected ver-
sus unaffected SSc skin was substantially lower than the
number of transcripts in affected SSc skin versus control
skin, indicating substantial heterogeneity in the group
with unaffected SSc skin. It is likely that a subgroup of
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SSc patients with clinically unaffected skin have histo-
logic changes characteristic of SSc.
In conclusion, this large global SSc skin gene
expression study indicated the presence of prominent
fibroinflammatory and keratin profiles. A subset of
patients with a longer disease duration had a normal-
like gene expression profile. Furthermore, analysis of
cell type–specific signature scores revealed significant
heterogeneity in the inflammatory profile of SSc skin,
which might provide important information for substra-
tifying patients to enable targeted therapies and to pre-
dict the response to immunosuppression.
ACKNOWLEDGMENTS
We thank Dr. Samuel Theodore for his assistance with
the data collection and Julio Charles for performing the laboratory
experiments. We are also grateful to Professor Lutz Langbein
(University of Heidelberg, Germany) for providing the KRT85
antibodies.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. Assassi had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Assassi, Tan, Furst, Mayes, Gudjons-
son, Chang.
Acquisition of data. Assassi, Tan, Khanna, Furst, Tashkin, Mayes.
Analysis and interpretation of data. Assassi, Swindell, Wu, Tan,
Jahan-Tigh, Mayes, Gudjonsson, Chang.
REFERENCES
1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in
mortality in patients with systemic sclerosis over 40 years: a sys-
tematic review and meta-analysis of cohort studies. Rheumatology
(Oxford) 2011;51:1017–26.
2. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshir-
ani R, et al. Use of gene-expression profiling to identify prog-
nostic subclasses in adult acute myeloid leukemia. N Engl J Med
2004;350:1605–16.
3. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann
WA, Espe KJ, et al. Interferon-inducible gene expression signa-
ture in peripheral blood cells of patients with severe lupus. Proc
Natl Acad Sci U S A 2003;100:2610–5.
4. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM,
Misek DE, et al. Gene-expression profiles predict survival of
patients with lung adenocarcinoma. Nat Med 2002;8:816–24.
5. Van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der
Voort LF, Killestein J, et al. Pharmacogenomics of interferon-b
therapy in multiple sclerosis: baseline IFN signature determines
pharmacological differences between patients. PLoS One 2008;3:
e1927.
6. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen
H, et al. Integrated genomic characterization of endometrial car-
cinoma. Nature 2013;497:67–73.
7. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M,
Trojanowska M, et al. Gene profiling of scleroderma skin reveals
robust signatures of disease that are imperfectly reflected in the
transcript profiles of explanted fibroblasts. Arthritis Rheum
2006;54:1961–73.
8. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM,
Feghali-Bostwick CA. Lung tissues in patients with systemic scle-
rosis have gene expression patterns unique to pulmonary fibrosis
and pulmonary hypertension. Arthritis Rheum 2011;63:783–94.
9. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont
TH, Connolly MK, et al. Molecular subsets in the gene expres-
sion signatures of scleroderma skin. PLoS One 2008;3:e2696.
10. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT,
Pergamenschikov A, et al. Systemic and cell type-specific gene
expression patterns in scleroderma skin. Proc Natl Acad Sci U S
A 2003;100:12319–24.
11. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK,
McNearney TA, et al. Systemic sclerosis and lupus: points in an
interferon-mediated continuum. Arthritis Rheum 2010;62:
589–98.
12. Christmann RB, Hayes E, Pendergrass S, Padilla C, Farina G,
Affandi AJ, et al. Interferon and alternative activation of mono-
cyte/macrophages in systemic sclerosis–associated pulmonary
arterial hypertension. Arthritis Rheum 2011;63:1718–28.
13. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C,
et al. Patients with systemic lupus erythematosus, myositis, rheu-
matoid arthritis and scleroderma share activation of a common
type I interferon pathway. Ann Rheum Dis 2011;70:2029–36.
14. Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F,
Lehmann KP, et al. The plasma cell signature in autoimmune
disease. Arthritis Rheumatol 2014;66:173–84.
15. Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C,
et al. Signatures of differentially regulated interferon gene
expression and vasculotrophism in the peripheral blood cells of
systemic sclerosis patients. Rheumatology (Oxford) 2006;45:694–
702.
16. Hinchcliff M, Huang CC, Wood TA, Mahoney JM, Martyanov V,
Bhattacharyya S, et al. Molecular signatures in skin associated
with clinical improvement during mycophenolate treatment in sys-
temic sclerosis. J Invest Dermatol 2013;133:1979–89.
17. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis
R, Whitfield ML. Intrinsic gene expression subsets of diffuse
cutaneous systemic sclerosis are stable in serial skin biopsies.
J Invest Dermatol 2012;132:1363–73.
18. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM,
Draeger HT, et al. Predictors of interstitial lung disease in early
systemic sclerosis: a prospective longitudinal study of the GENI-
SOS cohort. Arthritis Res Ther 2010;12:R166.
19. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian
P, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib
mesylate in the treatment of systemic sclerosis–associated active
interstitial lung disease. Arthritis Rheum 2011;63:3540–6.
20. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron
M, Tyndall A, et al. 2013 classification criteria for systemic scle-
rosis: an American College of Rheumatology/European League
Against Rheumatism collaborative initiative. Arthritis Rheum
2013;65:2737–47.
21. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T,
Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classifi-
cation, subsets, and pathogenesis. J Rheumatol 1988;15:202–5.
22. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin
R, et al. Inter and intraobserver variability of total skin thickness
score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol
1995;22:1281–5.
23. Tusher VG, Tibshirani R, Chu G. Significance analysis of micro-
arrays applied to the ionizing radiation response. Proc Natl
Acad Sci U S A 2001;98:5116–21.
24. Kenny PA, Enver T, Ashworth A. Receptor and secreted targets
of Wnt-1/b-catenin signalling in mouse mammary epithelial cells.
BMC Cancer 2005;5:3.
25. Swindell WR, Johnston A, Voorhees JJ, Elder JT, Gudjonsson
JE. Dissecting the psoriasis transcriptome: inflammatory- and
TRANSCRIPTOME PROFILING OF SYSTEMIC SCLEROSIS SKIN 3025
cytokine-driven gene expression in lesions from 163 patients.
BMC Genomics 2013;14:527.
26. Palmer C, Diehn M, Alizadeh AA, Brown PO. Cell-type specific
gene expression profiles of leukocytes in human peripheral
blood. BMC Genomics 2006;7:115.
27. Haider AS, Lowes MA, Suarez-Farinas M, Zaba LC, Cardinale
I, Blumenberg M, et al. Cellular genomic maps help dissect
pathology in human skin disease. J Invest Dermatol 2008;128:
606–15.
28. Swindell WR, Johnston A, Xing X, Voorhees JJ, Elder JT,
Gudjonsson JE. Modulation of epidermal transcription circuits
in psoriasis: new links between inflammation and hyperprolifera-
tion. PLoS One 2013;8:e79253.
29. Swindell WR, Stuart PE, Sarkar MK, Voorhees JJ, Elder JT,
Johnston A, et al. Cellular dissection of psoriasis for transcrip-
tome analyses and the post-GWAS era. BMC Med Genomics
2014;7:27.
30. Tabata H, Hara N, Otsuka S, Yamakage A, Yamazaki S, Koibuchi
N. Correlation between diffuse pigmentation and keratinocyte-
derived endothelin-1 in systemic sclerosis. Int J Dermatol 2000;39:
899–902.
31. Rudnicka L, Varga J, Christiano AM, Iozzo RV, Jimenez SA,
Uitto J. Elevated expression of type VII collagen in the skin of
patients with systemic sclerosis: regulation by transforming
growth factor-b. J Clin Invest 1994;93:1709–15.
32. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S,
Landthaler M, et al. Overexpression of monocyte chemoattrac-
tant protein 1 in systemic sclerosis: role of platelet-derived
growth factor and effects on monocyte chemotaxis and collagen
synthesis. Arthritis Rheum 2001;44:2665–78.
33. Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differen-
tial expression of VEGF, VEGFR-2, and GLUT-1 proteins in dis-
ease subtypes of systemic sclerosis. Hum Pathol 2006;37:190–7.
34. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott
H, et al. Expression of interleukin-21 receptor in epidermis from
patients with systemic sclerosis. Arthritis Rheum 2005;52:856–64.
35. Aden N, Shiwen X, Aden D, Black C, Nuttall A, Denton CP,
et al. Proteomic analysis of scleroderma lesional skin reveals
activated wound healing phenotype of epidermal cell layer.
Rheumatology (Oxford) 2008;47:1754–60.
36. Aden N, Nuttall A, Shiwen X, de Winter P, Leask A, Black CM,
et al. Epithelial cells promote fibroblast activation via IL-1a in
systemic sclerosis. J Invest Dermatol 2010;130:2191–200.
37. Hardy MH. The secret life of the hair follicle. Trends Genet
1992;8:55–61.
38. Lo CC, Prowse DM, Watt FM. Transient activation of b-catenin
signalling in adult mouse epidermis is sufficient to induce new
hair follicles but continuous activation is required to maintain
hair follicle tumours. Development 2004;131:1787–99.
39. Lowry WE, Blanpain C, Nowak JA, Guasch G, Lewis L, Fuchs
E. Defining the impact of b-catenin/Tcf transactivation on epi-
thelial stem cells. Genes Dev 2005;19:1596–611.
40. Van Mater D, Kolligs FT, Dlugosz AA, Fearon ER. Transient
activation of b-catenin signaling in cutaneous keratinocytes is
sufficient to trigger the active growth phase of the hair cycle in
mice. Genes Dev 2003;17:1219–24.
41. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff
ME, et al. Wnt/b-catenin signaling is hyperactivated in systemic
sclerosis and induces Smad-dependent fibrotic responses in mes-
enchymal cells. Arthritis Rheum 2012;64:2734–45.
3026 ASSASSI ET AL
